| Active substance | Berotralstat dihydrochloride |
| Holder | Biocryst Ireland Limited |
| Status | Running |
| Indication | Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 13/02/2024 |